Cryo-EM structures of somatostatin receptor 5 bound to pasireotide and octreotide at 3.09Å and 3.24Å resolution reveal why pasireotide preferentially targets SSTR5 — guiding design of more selective peptide drugs for Cushing's disease.
3.09Å resolutionThe cryo-EM structure of SSTR5 bound to pasireotide at 3.09Å resolution reveals atomic-level details of peptide-receptor binding that explain drug selectivity.
What the researchers found
Two cryo-EM structures were solved: SSTR5-Gi complex with pasireotide at 3.09Å resolution and SSTR5-Gi complex with octreotide at 3.24Å resolution. Structural analysis revealed that pasireotide's preferential binding to SSTR5 is mediated by interactions between its Tyr(Bzl) and DTrp residues and specific SSTR5 binding pocket features.
For octreotide's bias toward SSTR2, key residues were identified: Q2.63, N6.55, F7.35, and extracellular loop 2 (ECL2) of SSTR2 play crucial roles. These findings explain the molecular basis of peptide-receptor selectivity and provide specific structural targets for designing more selective SSTR5-targeted drugs.
Why it matters
Pasireotide is the only FDA-approved drug for Cushing's disease, but its side effects (especially hyperglycemia) limit its use. Understanding exactly how it binds SSTR5 at the atomic level enables rational design of next-generation somatostatin analogs with improved selectivity — drugs that target SSTR5 precisely without activating SSTR2 and causing metabolic side effects. This is structure-based drug design at its most impactful.
How the study worked
Cryo-electron microscopy was used to determine the 3D structures of SSTR5-Gi signaling complexes bound to pasireotide and octreotide. Structural analysis identified key binding interactions and selectivity determinants. Functional experiments validated the structural observations and tested the importance of specific residues for receptor activation and selectivity.
What this study cannot tell us
Cryo-EM structures capture a static snapshot of receptor-peptide interactions and may not fully represent the dynamic binding process. The structures were determined using purified receptor-Gi complexes, which may not perfectly replicate the cellular membrane environment. Functional validation was performed in cell lines (HEK293), not in disease-relevant pituitary tumor cells. The structural insights need to be translated into actual drug candidates and tested for improved selectivity in pharmacological studies.
How to read the evidence
This is a high-quality structural biology study using state-of-the-art cryo-EM methods with functional validation. The structural data is authoritative for understanding binding mechanisms, but translating these insights into improved drugs requires additional medicinal chemistry and pharmacological work.
When this study was published
Published in 2024, this is very recent and represents the current state of the art in GPCR structural pharmacology. These structures will serve as foundational references for SSTR5-targeted drug design for years to come.
The bigger picture
Somatostatin analogs have been a cornerstone of peptide therapeutics for decades, treating conditions from acromegaly to neuroendocrine tumors. But the five somatostatin receptor subtypes have overlapping drug responses, making selectivity a persistent challenge. These structures mark a significant advance in understanding SSTR subtype selectivity at the molecular level and join a growing library of GPCR-peptide complex structures that are revolutionizing peptide drug design across therapeutic areas.
Questions still open
- Can these structural insights be used to design an SSTR5-selective peptide that avoids SSTR2 activation and eliminates the hyperglycemia side effect?
- How do the dynamics of peptide binding and receptor activation complement the static structural snapshots provided by cryo-EM?
- Would similar cryo-EM approaches reveal selectivity mechanisms for other somatostatin receptor subtypes (SSTR1, SSTR3, SSTR4)?
Common questions
Why is it important to see how drugs bind to their receptor at the atomic level?
What are pasireotide and octreotide used for?
Read the original research
Structural insights into somatostatin receptor 5 bound with cyclic peptides.
Acta pharmacologica Sinica, 45(11), 2432-2440
Citation
Li, Ying-Ge; Meng, Xian-Yu; Yang, Xiru; Ling, Sheng-Long; Shi, Pan; Tian, Chang-Lin; Yang, Fan. (2024). Structural insights into somatostatin receptor 5 bound with cyclic peptides.. Acta pharmacologica Sinica, 45(11), 2432-2440. https://doi.org/10.1038/s41401-024-01314-8